
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp has demonstrated robust growth in its high-demand segments, particularly with the BioBrace product line, which is set for full FDA-approved release, signaling a promising expansion in rotator cuff repair offerings. Despite facing supply constraints, the Foot & Ankle segment achieved double-digit growth, reflecting resilience and a potential easing of operational challenges. Additionally, the company's conservative revenue guidance indicates a strategic focus on sustainable growth, suggesting management's confidence in a gradual improvement of top-line performance in the latter half of the year.
Bears say
Conmed Corp's stock has experienced a significant decline of approximately 27% year-to-date, reflecting ongoing struggles in the company's turnaround efforts. The company's recent pricing target has been reduced from $80 to $68, which indicates a downward adjustment in expectations based on its fiscal year 2025 earnings per share estimate of $4.46. Additionally, there has been observed capital weakness, particularly in international markets, attributed to challenging year-over-year comparisons rather than an overall slowdown in hospital capital budgets.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares